Healio (2/4, Gramigna) reports, “The COVID-19 pandemic appeared to shift ED use and priorities for care, particularly related to mental health, substance use and violence risk screening and prevention,” researchers concluded after capturing data on “187,508,065 ED visits, of which 6,018,318 included at least one study outcome, between December 30, 2018, and October 10, 2020.” After comparing “the median ED visit counts between March 15, 2020, and October 10, 2020, with the same period in 2019,” the study team “found that the 2020 counts were significantly higher for suicide attempts, all overdoses and opioid overdoses.” The findings were published online Feb. 3 in JAMA Psychiatry.

Related Links:

— “COVID-19 pandemic has shifted ED use related to mental health, substance use, violence “Joe Gramigna, Healio, February 4, 2021

The New York Times (2/3, A1, Forsythe, Bogdanich) reports, “McKinsey & Company, the consultant to blue-chip corporations and governments around the world, has agreed to pay $573 million to settle investigations into its role in helping ‘turbocharge’ opioid sales, a rare instance of it being held publicly accountable for its work with clients.” The firm “has reached the agreement with attorneys general in 47 states, the District of Columbia and five territories, according to five people familiar with the negotiations.” The settlement “comes after lawsuits unearthed a trove of documents showing how McKinsey worked to drive sales of Purdue Pharma’s OxyContin” pain medication “amid an opioid epidemic in the United States that has contributed to the deaths of more than 450,000 people over the past two decades.”

Related Links:

— “McKinsey Settles for Nearly $600 Million Over Role in Opioid Crisis ” Michael Forsythe and Walt Bogdanich, The New York Times, February 3, 2021

Healio (2/3, Miller) reports, “The percentage of fatal overdose cases in Philadelphia with detectable levels of xylazine rose from 2% to 31% during a 10-year period, suggesting that the United States’ opioid epidemic ‘continues to evolve,’” investigators concluded after analyzing “data on overdose deaths from heroin, fentanyl or both from the Philadelphia Medical Examiner’s Office.” The findings were published online in the journal Injury Prevention.

Related Links:

— “Xylazine found in one-third of fatal opioid overdoses in Philadelphia “Janel Miller, Healio, February 3, 2021

Reuters (2/3, Terhune, Levine) reports, “Newly unsealed court documents and other records show that Merck & Co and U.S. regulators knew about reports of suicidal behavior in men taking the company’s anti-baldness treatment Propecia [finasteride] when they decided not to warn consumers of those potential risks in a 2011” label update of the medication. In late January, “internal records from Merck were made public…when a federal magistrate in Brooklyn, New York, granted a 2019 Reuters motion to unseal 11 documents filed in years of litigation alleging Propecia caused persistent sexual dysfunction and other harmful side effects.” Following “the 2011 decision on the warning, the FDA has received more than 700 reports of suicide and suicidal thoughts among people taking Propecia or generic versions of the drug.”

Related Links:

— “Exclusive: Merck anti-baldness drug Propecia has long trail of suicide reports, records show ” Dan Levine, Chad Terhune, Reuters, February 3, 2021

CNN (2/2, Marples) reports a study by the Harvard School of Dental Medicine found “34% of adults ages 18 to 25 misused their psychoactive medications,” which include “opioids, stimulants, tranquilizers and sedatives.” The analysis of “surveys of U.S. youth and young adults taken between 2015 and 2018” also found “over 20% of youth ages 12 to 17 who took psychoactive medications were also found to be misusing these drugs.” The findings were published Tuesday in the British Medical Journal.

Related Links:

— “Over one-third of young adults misuse psychoactive medications, study says “Megan Marples, Megan Marples, February 2, 2021